{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:27:13Z","timestamp":1792682833469,"version":"4.5.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"\n Importance<\/jats:title>\n There is no US Food and Drug Administration\u2013approved treatment for pityriasis rubra pilaris (PRP), and it is common for patients to fail to experience improvement with several systemic options. Involvement of interleukin (IL) 23 suggests a potential therapeutic target.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether guselkumab, an IL-23p19 inhibitor, provides clinical improvement for participants with PRP and better understand gene and protein dysregulation in PRP.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This single-arm, investigator-initiated nonrandomized trial was conducted from October 2019 to August 2022 at a single-center academic university with participants from 8 states in the US. In total, 14 adults with moderate to severe PRP were enrolled; 12 completed the trial. Age-matched and sex-matched healthy controls provided skin and blood for proteomic and transcriptomic studies. The primary outcome was observed at 24 weeks, and additional follow-up occurred at 36 weeks.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Guselkumab is a fully human immunoglobulin G1 \u03bb monoclonal antibody that selectively binds and inhibits the p19 subunit of IL-23. Subcutaneous injections were given at the US Food and Drug Administration\u2013approved dosing schedule for psoriasis over a 24-week period.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the mean change in the Psoriasis Area Severity Index (PASI) score at week 24. Secondary outcomes included pruritus, Dermatology Life Quality Index score, clinical response at week 36, and association with transcriptomics and proteomics expression.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A per-protocol analysis was performed for the cohort of 4 female and 8 male patients who had a mean (SD) age of 56.5 (18.7) years. The mean improvement in PASI score, pruritus, and Dermatology Life Quality Index score was 61.8% (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), 62.3% (\n P<\/jats:italic>\n \u2009=\u2009.001), and 60.2% (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), respectively. Nine participants (75%) achieved a 50% improvement in PASI. Among these clinical responders, at week 36, 8 of 9 achieved PASI75, and 6 of 9 achieved PASI90. No participants had pathogenic\n CARD14<\/jats:italic>\n gene variations. There was 1 serious adverse event that was not associated with the study drug. Proteomics and gene expression profiles identified dysregulation of a predominance of inflammatory pathways (such as T helper 17 and nuclear factor \u03ba B) in participants with PRP who later responded well to treatment with guselkumab and stronger dysregulation of keratinocyte development pathways in individuals who did not respond to guselkumab.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n The results of this nonrandomized trial suggest that guselkumab has efficacy in treating refractory moderate to severe adult PRP.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03975153<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.0257","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T11:01:14Z","timestamp":1712746874000},"page":"641","source":"Crossref","is-referenced-by-count":13,"title":["Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23\/IL-17 and NFkB Signaling"],"prefix":"10.1001","volume":"160","author":[{"given":"Rose C.","family":"Velasco","sequence":"first","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Cutler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Strunck","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Kent","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela B.","family":"Cassidy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Choate","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri M.","family":"Greiling","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"dbr240003r1","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/bjd.21792","article-title":"Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris.","volume":"187","author":"Ji-Xu","year":"2022","journal-title":"Br J Dermatol"},{"key":"dbr240003r2","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.v2.1","article-title":"The comprehensive impact of pityriasis rubra pilaris on physical symptoms, mental health, and activities of daily living: a mixed methods study.","author":"Velasco","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"20","key":"dbr240003r3","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.151911","article-title":"Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.","volume":"6","author":"Shao","year":"2021","journal-title":"JCI Insight"},{"issue":"3","key":"dbr240003r4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jid.2022.09.005","article-title":"Pityriasis rrubra pilaris transcriptomics implicate T helper 17 signaling and correlate with response to ixekizumab, with distinct gene expression profiles in nonresponders.","volume":"143","author":"Haynes","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"10201","key":"dbr240003r5","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"dbr240003r6","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1001\/jamadermatol.2019.2774","article-title":"Treatment of pityriasis rubra pilaris with guselkumab.","volume":"155","author":"Pilz","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"6","key":"dbr240003r7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v33.6","article-title":"Successful treatment of pityriasis rubra pilaris with guselkumab: serum CCL20 as a potential marker for the disease activity.","volume":"33","author":"Nagai","year":"2020","journal-title":"Dermatol Ther"},{"issue":"4","key":"dbr240003r8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/ajd.v63.4","article-title":"Efficacy of ustekinumab and guselkumab in treatment refractory pityriasis rubra pilaris: a case series.","volume":"63","author":"Pham","year":"2022","journal-title":"Australas J Dermatol"},{"issue":"10","key":"dbr240003r9","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.v10.10","article-title":"Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris.","volume":"10","author":"Nishimura","year":"2022","journal-title":"Clin Case Rep"},{"issue":"2","key":"dbr240003r10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis.","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"dbr240003r11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ced.1994.19.issue-3","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"dbr240003r12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamadermatol.2020.0932","article-title":"Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial.","volume":"156","author":"Haynes","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"dbr240003r13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjd.21708","article-title":"Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.","volume":"187","author":"Boudreaux","year":"2022","journal-title":"Br J Dermatol"},{"issue":"5","key":"dbr240003r14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1684\/ejd.2019.3641","article-title":"Treatment of pityriasis rubra pilaris type I: a systematic review.","volume":"29","author":"Engelmann","year":"2019","journal-title":"Eur J Dermatol"},{"issue":"3","key":"dbr240003r15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ddg.2019.17.issue-3","article-title":"Systemic therapies of pityriasis rubra pilaris: a systematic review.","volume":"17","author":"Kromer","year":"2019","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2817330\/jamadermatology_velasco_2024_br_240003_1717692739.08588.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T11:01:04Z","timestamp":1718794864000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2817330"}},"subtitle":["A Nonrandomized Trial"],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.0257","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}